Scientists divulge latest in HIV prevention

July 25, 2017
HIV infecting a human cell. Credit: NIH

A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Moving away from the message to "Abstain, Be faithful, Condomise", modern prevention strategies include drug-doused vaginal rings, male circumcision, and taking anti-retroviral therapy (ART) medication, experts said at a HIV science conference in Paris.

Thirty-five years of research has yet to yield a cure or vaccine for the virus which has infected more than 76 million people since the early 1980s, and killed 35 million.

This means that prevention remains "absolutely critical," according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland, who attended the International AIDS Society conference.

There are 19.5 million people on ART today, with another 17.1 million who need it.

"Each year we add about two million to that group," Fauci told AFP. "We must decrease the number of new infections."

Some recent advances:


According to the World Health Organization, there is "compelling evidence" that reduces the risk of sexual HIV infection in heterosexual men.

On Tuesday, researchers said it also protects their female partners.

In a study with nearly 10,000 people in South Africa, women who reported that their most recent male sexual partner was circumcised were 22 percent less likely to have HIV and 15 percent less likely to have genital herpes than women whose last partner was not.

The reason is not clear. Is it simply that fewer men are being infected and infecting others in turn, or does circumcision actively prevent HIV-positive men from passing on the virus?

Research will continue, said Ayesha Kharsany of the CAPRISA research centre in South Africa.

"What is certain, however, is that having a circumcised partner can provide women with partial protection against HIV," she told journalists in Paris.

Some 12 million men have been medically circumcised in sub-Saharan Africa to date in an effort to stop the spread of HIV, Kharsany said.

Opposites attract

A study of gay couples in which one partner had HIV, showed that infected men who achieve virus suppression with ART also protected their uninfected partners.

"There were no, zero, HIV transmissions within these couples," said Andrew Grulich of the University of New South Wales in Australia, who took part in the study entitled "Opposites Attract".

Grulich and a team followed 330 couples for about 1.5 years, during which time the participants reported 17,000 acts of condomless, anal sex.

The lack of HIV spread was despite high rates of other sexually-transmissible infections, the team found.

"We think these findings really strongly support the hypothesis that condomless sex, when the viral load is undetectable, is a form of ," said Grulich.

Vaginal ring

A two-year study of 96 girls aged 15 to 17 in the United States, showed that a vaginal ring treated with the ARV drug dapivirine, was safe and easy to wear.

The ring is worn constantly, and replaced monthly.

In previous research involving adult women, the ring reduced the risk of acquiring HIV by about 30 percent, according to the research team. Further study is needed to test whether it also protected girls.

"HIV doesn't distinguish between a 16-year-old and an 18-year-old," said Sharon Hillier of the University of Pittsburgh School of Medicine.

"Young women of all ages deserve to be protected."

Teenage girls and young women aged 15-24 accounted for a fifth of new HIV infections among adults in 2015—rising to one in four in sub-Saharan Africa where 1,000 are infected daily, according to the study authors.

Injectable shield

A long-acting, injectable dose of the virus-suppressing drug cabotegravir, given every two months, was well tolerated in trial participants, according to early results.

Cabotegravir is being probed as an alternative to oral ARV as prevention—also known as pre-exposure prophylaxis or PrEP. Forgetting to take a pill can expose one to infection, and is a major complaint of PrEP users.

Further trials are in the pipeline to test the drug's virus-suppressing efficacy, said Raphael Landovitz, an expert from the University of California.

Less frequent sex

A drug cocktail that has been shown to protect uninfected gay men who engaged in frequent and "high-risk" sexual behaviour, also shields those who are less active and hence take fewer tablets, another study showed.

The IPERGAY trial is testing the efficacy of the drug cocktail Truvada taken as prevention before and after sex.

No infections were reported among men on PrEP who had sex about five times a month, researchers found. The team had previously measured a near 90-percent drop in infection risk for Truvada-users who had sex on average twice as often.

Explore further: HIV prevention dapivirine vaginal ring found safe and acceptable in US adolescent girls

Related Stories

HIV prevention dapivirine vaginal ring found safe and acceptable in US adolescent girls

July 25, 2017
A vaginal ring that researchers are hopeful will be approved as a method for preventing HIV in women was found to be safe and acceptable in teen girls, according to results of a study conducted in the United States and reported ...

Swaziland halves world's highest HIV infection rate: report

July 24, 2017
Swaziland, which bears the world's heaviest HIV burden, has almost halved the rate of new infections in five years by boosting access to virus-suppressing drugs, researchers said Monday.

NIH launches first large trial of a long-acting injectable drug for HIV prevention

December 20, 2016
The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational ...

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

MTN begins first trial of new dapivirine ring with both anti-HIV drug and contraceptive

May 3, 2017
Researchers hoping for a single product that women could use to protect against both HIV and unintended pregnancy took an important step toward realizing their goal with the start of the first trial of a vaginal ring containing ...

Europe's medicine watchdog okays preventive AIDS pill

July 22, 2016
Europe's medicines watchdog said Friday it has recommended the licencing of the first-ever AIDS prevention pill for the European Union.

Recommended for you

New simulation tool predicts how well HIV-prophylaxis will work

June 14, 2018
A new mathematical simulation approach predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, which help prevent HIV infection. The framework, presented in PLOS Computational Biology by Sulav Duwal ...

Many at risk for HIV despite lifesaving pill

June 11, 2018
Multiple barriers may stop high-risk individuals from accessing an HIV drug that can reduce the subsequent risk of infection, according to a new University of Michigan study.

Active HIV in large white blood cells may drive cognitive impairment in infected mice

June 7, 2018
Macrophages, large white blood cells that engulf and destroy potential pathogens, harbor active viral reserves that appear to play a key role in impaired learning and memory in mice infected with a rodent version of HIV. ...

HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains

June 4, 2018
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported ...

HIV study reveals new group of men at risk of infection

June 4, 2018
A group of men who may be underestimating their HIV risk has been identified in a new study.

Discovery reveals how cells try to control levels of key HIV protein

May 31, 2018
One of the many challenges in treating HIV is that the virus can lie dormant in cells, quietly evading immune detection until it suddenly roars to life without warning and begins replicating furiously. Salk Institute researchers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.